Cellectar Biosciences (CLRB) Preferred Stock Liabilities (2021 - 2025)

Cellectar Biosciences has reported Preferred Stock Liabilities for 5 years, with the latest figure at $1.4 million in Q4 2025.

• Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.4 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities steadied at $1.4 million in Q4 2025 per CLRB's latest filing, from $1.4 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $19.2 million in Q3 2023 and troughed at $1.4 million in Q4 2021.
• A 5-year average of $2.4 million and a median of $1.4 million in 2021 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2023 and 2024: Preferred Stock Liabilities soared 1289.41% in 2023, then slumped 92.8% in 2024.
• Over 5 years, Preferred Stock Liabilities stood at $1.4 million in 2021, then changed by 0.0% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $1.4 million, $1.4 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.